18 male albino rats (3 groups of six rats each) were fed with a control diet and one containing 12500 or 50000 ppm of unlabelled product for a period over 35 days. ... 10% were excreted as a glucuronide conjugate in the urine.
IDENTIFICATION AND USE: Octabenzone forms crystals. It is used as UV stabilizer for polyethylene, polypropylene. HUMAN EXPOSURE AND TOXICITY: Octabenzone did not induce chromosomal aberrations in human lymphocytes in vitro. ANIMAL STUDIES: The acute oral toxicity of octabenzone in rats was low. Dietary exposure of rats for 14 weeks resulted in kidney effects in males at 100 mg/kg-bw/day. Two 3-month dietary studies in rats showed no adverse effects. In a 30-day dietary study in rats, hematuria was seen at approximately 1220 mg/kg-bw/day. In Beagle dogs, dietary exposure for 124-127 days showed no effects at 150 mg/kg-bw/day. Octabenzone did not induce gene mutations in bacteria. Octabenzone acted as a skin sensitizer based on two guinea pig maximization assays. ECOTOXICITY STUDIES: The 96-hour LC50 for fish is = 0.003 mg/L. The 48-hour EC50 for aquatic invertebrates is = 0.003 mg/L. The 72-hour EC50 for aquatic plants = 0.002 mg/L.
Sunscreen compounds with added benefit of skin cancer prevention have both public and commercial interests. ... Earlier study using the Epstein-Barr virus early antigen in vitro assay reported on skin cancer chemoprevention potential of benzophenone sunscreens. We now report the in vivo antitumor activity of two of the benzophenone sunscreens which tested positively in the in vitro assay, octabenzone (UV-1) and dioxybenzone (UV-2), in the two-stage mouse skin carcinogenesis model using (+/-)-(E)-4-methyl-2-[-(E)-hydroxyamino]-5-nitro-6-methoxy-3-hexanamide (NOR-1) as inducer and 12-O-tetradecanoyl-phorbol-13-acetate (TPA) as promoter. Pathogen-free, female hairless mice of HOS:HR-1 strain, 15 animals per control and test groups, were used. Skin tumors were induced by a single dose of NOR-1 (390 nmol in 100 uL of acetone). One week later, TPA (1.7 nmol in 100 uL of acetone) was applied to skin twice weekly for 20 weeks as tumor promoter. The test compounds UV-I or UV-2 were administered at 0.0025% to mice through drinking water ad libitum, starting one week prior to and stopping one week after tumor initiation. All animals were examined weekly for the development of skin papillomas. In both UV-1- and UV-2-treated mice, a two-week delay in tumor appearance, and significant inhibition (p<0.001) of tumor incidence (50% and 60%, respectively) and tumor burden (papilloma inhibition/mouse, 50% and 70%, respectively) were observed when compared to the positive control group. UV-2 (dihydroxy derivative) was a more potent inhibitor of skin tumor than UV-1 (monohydroxy derivative), which followed their antioxidant activity ranking. The results affirm the skin cancer chemoprevention potential of orally-ingested benzophenone sunscreens in mice and warrant studies in humans to validate synergistic protection achievable by complementation of oral and topical sunscreen.
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand-valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR as necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Aromatic hydrocarbons and related compounds/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool. Administer activated charcoal ... . /Aromatic hydrocarbons and related compounds/
18 male albino rats (3 groups of six rats each) were fed with a control diet and one containing 12500 or 50000 ppm of unlabelled product for a period over 35 days. /Test chemical/ is weakly absorbed after oral administration. Up to 90% were recovered unchanged from the feces. 10% were excreted as a glucuronide conjugate in the urine. The total recovery of 100% of the test article indicates that the product is not accumulated in the body.
PHOTOPROTECTIVE COMPOSITIONS COMPRISING PHOTOSENSITIVE 1,3,5-TRIAZINE COMPOUNDS, DIBENZOYLMETHANE COMPOUNDS AND SILICEOUS S-TRIAZINES SUBSTITUTED WITH TWO AMINOBENZOATE OR AMINOBENZAMIDE GROUPS
申请人：L'OREAL
公开号：US20170135933A1
公开（公告）日：2017-05-18
UV-photoprotective, topically applicable cosmetic/dermatological compositions contain:
(a) at least one dibenzoylmethane compound,
(b) at least one 1,3,5-triazine compound that is photosensitive in the presence of a dibenzoylmethane compound, and
(c) at least one siliceous s-triazine compound substituted with two aminobenzoate or aminobenzamide groups, or a tautomeric form thereof, the 1,3,5-triazine compounds being improvedly photostable in such compositions.
Synthesis and Reactivity of α‐Cumyl Bromodifluoromethanesulfenate: Application to the Radiosynthesis of [
<sup>18</sup>
F]ArylSCF
<sub>3</sub>
作者：Jiang Wu、Qunchao Zhao、Thomas C. Wilson、Stefan Verhoog、Long Lu、Véronique Gouverneur、Qilong Shen
DOI：10.1002/anie.201813708
日期：2019.2.18
A highly reactive electrophilic bromodifluoromethylthiolating reagent, α-cumyl bromodifluoro-methanesulfenate 1, was prepared to allow for direct bromodifluoromethylthiolation of aryl boron reagents. This coupling reaction takes place under copper catalysis, and affords a large range of bromodifluoromethylthiolated arenes. These compounds are amenable to various transformations including halogen exchange
A compound represented by the following Formula (1):
wherein, Het
1
represents a bivalent five- or six-membered aromatic heterocyclic residue and may further be substituted; X
a
to X
d
each independently represent a heteroatom and may further be substituted; Y
a
to Y
f
each independently represent a heteroatom or a carbon atom and may further be substituted; the ring bound to Het
1
may have a double bond at any position
[EN] HEMI-AMINAL ETHERS AND THIOETHERS OF N-ALKENYL CYCLIC COMPOUNDS<br/>[FR] ÉTHERS ET THIOÉTHERS HÉMIAMINAUX DE COMPOSÉS CYCLIQUES N-ALCÉNYLIQUES
申请人：ISP INVESTMENTS INC
公开号：WO2014116560A1
公开（公告）日：2014-07-31
Described herein are hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds that may be produced through a reaction comprising: (A) at least one first reactant represented by a structure (I), wherein X is a functionalized or unfunctionalized C1-C5 alkylene group optionally having one or more heteroatoms, and each R1, R2, and R3 is independently selected from the group consisting of hydrogen and functionalized and unfunctionalized alkyl groups optionally having one or more heteroatoms, and (B) at least one second reactant having at least one hydroxyl moiety or thiol moiety. The hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds may comprise a polymerizable moiety, in which case they may be left as-is or used to create homopolymers or non-homopolymers, or they may not comprise a polymerizable moiety. A wide variety of formulations may be created using the hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds, including personal care, oilfield, and construction formulations.
The present invention relates to extracts of
Isochrysis
sp., preferably Tahitian
Isochrysis,
its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of
Isochrysis
sp., preferably Tahitian
Isochrysis.
